Table 1. Baseline characteristics of the patients analysed for survival-related end points.
| Characteristics | All patients, n=1303 |
|---|---|
| Sex, male | 880 (68%) |
| Age, mean±s.d. | 63±12 |
| Albumin, <3.5 g dl−1 | 317 (24%) |
| ECOG-PS ⩾2 | 188 (14%) |
| Primary tumour site | |
| Gastroesophageal junction | 138 (11%) |
| Stomach | 1165 (89%) |
| Stage at diagnosis, metastatic | 1236 (95%) |
| Surgery of primary tumour | 494 (38%) |
| Chemotherapy schedules | |
| Oxaliplatin-based | 459 (35%) |
| Anthracycline-based | 344 (26%) |
| Cisplatin-based | 191 (15%) |
| Docetaxel-based | 213 (16%) |
| Irinotecan-based | 29 (2%) |
| Other | 67 (5%) |
| Prior perioperative treatment | 155 (12%) |
| Lauren classification | |
| Intestinal | 482 (37%) |
| Diffuse | 652 (50%) |
| Indeterminate | 169 (13%) |
| Histological grade | |
| Grade 1 | 102 (8%) |
| Grade 2 | 340 (26%) |
| Grade 3 | 580 (44%) |
| Not available | 281 (22%) |
| Presence of signet ring cells | |
| No signet ring cells | 660 (50%) |
| Signet ring cells (<50%) | 103 (8%) |
| Signet ring cells (⩾50%) | 152 (12%) |
| Signet ring cells present with unknown percentage | 202 (16%) |
| Not available | 186 (14%) |
| Site of metastases | |
| Liver | 414 (32%) |
| Peritoneum | 641 (49%) |
| Bone | 128 (10%) |
| Lung | 98 (8%) |
| Tumour measurability | |
| Only non-measurable disease | 376 (29%) |
| Measurable disease | 927 (71%) |
| Measurable disease & response assessment available at 3 months | 730 (56%) |
Abbreviations: ECOG-PS=Eastern Cooperative Group Performance Status; g dl−1=grams per decilitre.